Supernus Pharmaceuticals (NASDAQ: SUPN ) received positive topline results from its Phase IIb study on SPN-810 for the treatment of impulsive aggression in ADHD patients. The study is a multicenter randomized, double-blind, placebo controlled clinical trial in children 6 to 12 diagnosed with Attention Deficit and Hyperactivity Disorder (ADHD) and